Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,237,933
  • Shares Outstanding, K 80,666
  • Annual Sales, $ 1,140 K
  • Annual Income, $ -88,040 K
  • EBIT $ -180 M
  • EBITDA $ -185 M
  • 60-Month Beta 1.29
  • Price/Sales 2,836.41
  • Price/Cash Flow N/A
  • Price/Book 4.44

Options Overview Details

View History
  • Implied Volatility 66.17% (-1.01%)
  • Historical Volatility 50.18%
  • IV Percentile 33%
  • IV Rank 15.86%
  • IV High 147.24% on 04/22/25
  • IV Low 50.89% on 08/18/25
  • Expected Move (DTE 21) 4.61 (11.48%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 62
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 26,779
  • Open Int (30-Day) 24,252
  • Expected Range 35.53 to 44.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.63
  • Number of Estimates 8
  • High Estimate -0.56
  • Low Estimate -0.70
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.01 +8.46%
on 12/17/25
46.01 -12.76%
on 12/05/25
-4.70 (-10.48%)
since 11/26/25
3-Month
35.80 +12.12%
on 11/11/25
46.01 -12.76%
on 12/05/25
+2.60 (+6.93%)
since 09/26/25
52-Week
14.80 +171.22%
on 04/09/25
46.01 -12.76%
on 12/05/25
+11.03 (+37.89%)
since 12/26/24

Most Recent Stories

More News
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Applications for the fellowship are due on...

CGON : 40.14 (unch)
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates...

CGON : 40.14 (unch)
CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CGON : 40.14 (unch)
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting

IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 40.14 (unch)
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated...

CGON : 40.14 (unch)
Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (RBRK) and CG Oncology, Inc. (CGON)

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Rubrik, Inc. Class A (RBRK – Research Report) and CG Oncology, Inc. (CGON – Research Report) with bullish sentiments.Elevate...

CGON : 40.14 (unch)
RBRK : 78.31 (-0.62%)
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

/CNW/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...

ONCY : 0.9894 (+2.00%)
IDYA : 35.68 (unch)
HCM : 13.52 (+0.30%)
CGON : 40.14 (unch)
CCCC : 2.08 (+2.97%)
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

ONCY : 0.9894 (+2.00%)
IDYA : 35.68 (unch)
HCM : 13.52 (+0.30%)
CGON : 40.14 (unch)
CCCC : 2.08 (+2.97%)
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 40.14 (unch)
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ...

CGON : 40.14 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 41.41
2nd Resistance Point 40.99
1st Resistance Point 40.56
Last Price 40.14
1st Support Level 39.71
2nd Support Level 39.29
3rd Support Level 38.86

See More

52-Week High 46.01
Last Price 40.14
Fibonacci 61.8% 34.09
Fibonacci 50% 30.40
Fibonacci 38.2% 26.72
52-Week Low 14.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar